Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY 4.0Journal of Neural Transmission

Population pharmacokinetic analyses comparing immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and IPX203. Findings from a phase 1 study in healthy volunteers

  1. 11A Consulting, Dr Wach & Wach GbR, Weil am Rhein, Germany
  2. 2Zambon Biotech SA, Medical Affairs, Cadempino, Switzerland
  3. 3Institute of Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, SE1 1UL UK

Abstract

Optimizing oral levodopa delivery by prolonging duration of effect remains a key challenge in managing OFF periods in Parkinson’s disease. IPX203 is an oral modified-release formulation combining immediate-release (IR) and extended-release (ER) levodopa with IR carbidopa, designed to provide rapid onset and sustained exposure. We characterized pharmacokinetics of levodopa and carbidopa following IPX203 compared with IR and controlled-release (CR) levodopa/carbidopa using population pharmacokinetic modeling from a Phase 1 study in healthy volunteers. Plasma concentration–time data were analyzed using nonlinear mixed-effects modeling. Formulation-specific absorption models, including a dual-depot model for IPX203, were combined with a shared systemic disposition model. The models adequately described observed levodopa and carbidopa concentrations across formulations. Marked formulation-dependent differences in levodopa exposure were driven by absorption. IR-levodopa/carbidopa produced rapid absorption with peak concentrations followed by a steep decline, consistent with elimination-rate–limited pharmacokinetics. CR-levodopa/carbidopa showed delayed absorption with lower peak concentrations and limited time within the expected therapeutic range (750–1000 ng/mL). In contrast, IPX203 exhibited biphasic absorption, with an initial IR-driven peak and sustained concentrations from the ER component, consistent with rate-limited absorption and prolonged intestinal residence. This resulted in reduced peak–trough fluctuation and longer duration within therapeutic range. Carbidopa profiles were qualitatively similar, with higher absolute exposure for IPX203. Model-based simulations of commonly used dosing regimens suggested that IPX203 administered every 6 h achieved the most stable levodopa concentrations. These findings indicate that IPX203 provides a distinct exposure profile characterized by rapid onset and sustained levodopa exposure driven by controlled absorption.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s00702-026-03233-w.

Related

  1. Comparing Machine Learning and Population Pharmacokinetic Approaches for Drug Concentration Prediction in Dense and Sparse Data Settings
    Shuqi Huang, Qihan Xu, Shengnan Zhang +3
    Clinical Pharmacology and TherapeuticsPeer-reviewedLicence not statedFull textObstetrics, gynaecology & paediatricsPMC
  2. Randomized, Controlled, Crossover Trial Comparing Immediate Effects of Components of Complex Decongestive Therapy in Lower-limb Lymphedema Patients.
    Asako Oka, Tetsuya Tsuji, Kiriko Abe +8
    Progress in rehabilitation medicinePeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCPMC
  3. Comparing the Predictive Performance of Machine Learning Models with a Newly Developed Population Pharmacokinetic Model for Busulfan in Paediatric Patients
    Tianwu Yang, Maria Thastrup, Tania Nicole Masmas +6
    Clinical PharmacokineticsPeer-reviewedCC BY-NC 4.0Full textObstetrics, gynaecology & paediatricsPMC
  4. Comparing aggregated and nonlinear measures of coordinative behaviors in immediate responder first aid groups: a controlled experimental simulation study.
    Wilhelm Brodin, Fredrik Fernlund, Carl-Oscar Jonson +1
    Advances in simulation (London, England)Peer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  5. Buccal and sublingual lyophilised naloxone for opioid overdose reversal: A Phase 1 open-label, random-sequence crossover pharmacokinetic study protocol in healthy volunteers (NalBuc)
    Mariana Gonzalez Utrilla, Alexander Baker, Edward Chesney +3
    PLOS OnePeer-reviewedCC BY 4.0Full textGeneral biologyClinical trials & evidence synthesisPLOSPMC
BibTeX
@article{wach2026population,
  title = {{Population pharmacokinetic analyses comparing immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and IPX203. Findings from a phase 1 study in healthy volunteers}},
  author = {Achim Wach and Jaakko Kopra and Ivan Marjanovic and Mathias Knecht and Peter Jenner},
  journal = {Journal of Neural Transmission},
  year = {2026},
  month = jul,
  doi = {10.1007/s00702-026-03233-w},
  url = {https://doi.org/10.1007/s00702-026-03233-w},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Population pharmacokinetic analyses comparing immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and IPX203. Findings from a phase 1 study in healthy volunteers
AU  - Achim Wach
AU  - Jaakko Kopra
AU  - Ivan Marjanovic
AU  - Mathias Knecht
AU  - Peter Jenner
PY  - 2026
DA  - 2026/07/21
JO  - Journal of Neural Transmission
DO  - 10.1007/s00702-026-03233-w
UR  - https://doi.org/10.1007/s00702-026-03233-w
AB  - Optimizing oral levodopa delivery by prolonging duration of effect remains a key challenge in managing OFF periods in Parkinson’s disease. IPX203 is an oral modified-release formulation combining immediate-release (IR) and extended-release (ER) levodopa with IR carbidopa, designed to provide rapid onset and sustained exposure. We characterized pharmacokinetics of levodopa and carbidopa following IPX203 compared with IR and controlled-release (CR) levodopa/carbidopa using population pharmacokinetic modeling from a Phase 1 study in healthy volunteers. Plasma concentration–time data were analyzed using nonlinear mixed-effects modeling. Formulation-specific absorption models, including a dual-depot model for IPX203, were combined with a shared systemic disposition model. The models adequately described observed levodopa and carbidopa concentrations across formulations. Marked formulation-dependent differences in levodopa exposure were driven by absorption. IR-levodopa/carbidopa produced rapid absorption with peak concentrations followed by a steep decline, consistent with elimination-rate–limited pharmacokinetics. CR-levodopa/carbidopa showed delayed absorption with lower peak concentrations and limited time within the expected therapeutic range (750–1000 ng/mL). In contrast, IPX203 exhibited biphasic absorption, with an initial IR-driven peak and sustained concentrations from the ER component, consistent with rate-limited absorption and prolonged intestinal residence. This resulted in reduced peak–trough fluctuation and longer duration within therapeutic range. Carbidopa profiles were qualitatively similar, with higher absolute exposure for IPX203. Model-based simulations of commonly used dosing regimens suggested that IPX203 administered every 6 h achieved the most stable levodopa concentrations. These findings indicate that IPX203 provides a distinct exposure profile characterized by rapid onset and sustained levodopa exposure driven by controlled absorption.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s00702-026-03233-w.
SN  - 0300-9564
SN  - 1435-1463
ER  -